stockrowSutro Biopharma, Inc.
STROSutro Biopharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $102.5 million, up 65.2% from fiscal 2024.
- Revenue
- −84.6%
- EPS
- −66.4%
- Free cash flow
- +14.6%
Quarter to June 2026, against a year earlier
Follow STRO
Alert me
Sutro Biopharma, Inc. (STRO) EV/Sales
As of 6 November 2026, Sutro Biopharma, Inc. (STRO) trades at a EV/Sales of 0.1×. Over the past ten years it has ranged from −4.5× (November 2023) to 17.3× (April 2021); the current reading is higher than 42% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | −0.3× | — |
| FY2024 | −2.7× | — |
| FY2023 | −0.6× | — |
| FY2022 | 1.3× | (84.20%) |
| FY2021 | 8.3× | (2.77%) |
| FY2020 | 8.5× | 152.27% |
| FY2019 | 3.4× | — |
| FY2018 | −3.6× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 8.6× | 554.19% |
| Mar 2026 | 1.3× | — |
| Dec 2025 | −0.3× | — |
| Sep 2025 | −0.8× | — |
| 31 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| ANTX AN2 Therapeutics, Inc. compare | n/m |
| SION Sionna Therapeutics, Inc. compare | n/m |
| PEPG PepGen, Inc. compare | n/m |
| CNTN Canton Strategic Holdings, Inc. compare | n/m |
| STRO Sutro Biopharma, Inc. | 0.1× |
| IPHA Innate Pharma S.A. Sponsored ADR compare | 0.1× |
| ALXO ALX Oncology Holdings Inc. compare | 14.0× |
| ORMP Oramed Pharmaceuticals Inc. compare | 26.8× |
| INO Inovio Pharmaceuticals, Inc. compare | 206× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)